Wedbush Starts Novavax (NVAX) at Outperform; Continued Value From Ongoing Partnerships
Tweet
Share
E-mailGet Alerts NVAX Hot Sheet
Price: $4.15 -0.95%
Rating Summary:
9 Buy, 4 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
9 Buy, 4 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
Wedbush initiates coverage on Novavax (NASDAQ: NVAX) with a Outperform. PT $6.
Wedbush analyst says, "NVAX represents an international growth story positioned to take advantage of the largely untapped, rapidly growing emerging market opportunity for seasonal and pandemic influenza vaccines and production capacity. The company has several joint ventures outside the US, including an Indian market joint venture with Cadila Pharmaceuticals (India) and the recently announced partnership with LG Life Sciences in the South Korean market."
"The next major events for the stock include initiation of a Phase III clinical
trial for a NVAX’s VLP seasonal flu vaccine, H1N1 seasonal vaccine marketing approval in Mexico and the possible announcement of a US or EU partnership or licensing agreement."
For more ratings news on Novavax click here and for the rating history of Novavax click here.
Shares of Novavax closed at $2.48 yesterday.
Wedbush analyst says, "NVAX represents an international growth story positioned to take advantage of the largely untapped, rapidly growing emerging market opportunity for seasonal and pandemic influenza vaccines and production capacity. The company has several joint ventures outside the US, including an Indian market joint venture with Cadila Pharmaceuticals (India) and the recently announced partnership with LG Life Sciences in the South Korean market."
"The next major events for the stock include initiation of a Phase III clinical
trial for a NVAX’s VLP seasonal flu vaccine, H1N1 seasonal vaccine marketing approval in Mexico and the possible announcement of a US or EU partnership or licensing agreement."
For more ratings news on Novavax click here and for the rating history of Novavax click here.
Shares of Novavax closed at $2.48 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DAM Capital Starts Apollo Tyres (APTY:IN) at Buy
- BofA Securities Assumes Altice-USA (ATUS) at Underperform
- JPMorgan Starts Lovisa Holdings Ltd (LOV:AU) at Neutral
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
